Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.8
3.1
Journals
Materials
Special Issues
Development and Applications of Nanomaterials for Novel Cancer Therapies
materials-logo
Submit to Materials Review for Materials Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Development and Applications of Nanomaterials for Novel Cancer Therapies

A special issue of Materials (ISSN 1996-1944). This special issue belongs to the section "Biomaterials".

Deadline for manuscript submissions: closed (20 November 2021) | Viewed by 4531

Special Issue Editors

Prof. Dr. Wei R. Chen

E-Mail Website
Guest Editor
Stephenson School of Biomedical Engineering, Gallogly College of Engineering,University of Oklahoma, Norman, OK, USA
Interests: immunologically modified nanomaterials for cancer; laser immunotherapy for metastatic cancers; antitumor immune responses induced by phototherapy; laser induced tumor microenvironment changes
Prof. Dr. Feifan Zhou

E-Mail Website
Guest Editor
School of Biomedical Engineering, Hainan University, Haikou 570228, China
Interests: nanomaterials based cancer phototherapy; synergized phototherapy and immunotherapy for metastatic cancer; mechnism of cancer photoimmunotherapy; imaging-guided cancer therapy

Special Issue Information

Dear Colleagues,

The past several decades have witnessed the development and applications of nanomaterials in medicine. Particularly, nanomaterials for cancer therapies have been emerging and have received considerable attention in recent years. As the core of cancer nanotechnology, nanoplatform design and application are interdisciplinary in nature, encompassing the research areas of biology, chemistry, engineering, and medicine. Nanomaterials can be designed to have specific optical, physicochemical, biological, and pharmaceutical properties; they can be used in phototherapy, chemotherapy, immunotherapy, and in combination therapy. Nanomaterials mark a significant step forward in novel cancer therapies and show great potential in clinical applications. The opportunities and challenges to overcome malignant cancers drive the development of nanotechnology-based novel cancer therapies. More and more researchers are attracted to research in this area. 

This Special Issue will focus on the development and applications of nanomaterials for novel cancer therapies. Welcome in this Special Issue are regular research articles, regular or mini reviews, case reports, and technical reports.

Prof. Dr. Wei R. Chen
Prof. Dr. Feifan Zhou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials for targeted therapy
  • nanoparticle-based immunotherapy
  • image-guided cancer therapy
  • multimodality nanoplatforms for combination cancer therapy
  • nanodrug delivery and release
  • quantification of nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 3279 KiB  
Article
Doxorubicin-Loaded Metal-Organic Framework Nanoparticles as Acid-Activatable Hydroxyl Radical Nanogenerators for Enhanced Chemo/Chemodynamic Synergistic Therapy
by Honghui Li, Ying Zhang, Lingxia Liang, Jiaxing Song, Zixuan Wei, Shuyue Yang, Yunong Ma, Wei R. Chen, Cuixia Lu and Liewei Wen
Materials 2022, 15(3), 1096; https://doi.org/10.3390/ma15031096 - 30 Jan 2022
Cited by 22 | Viewed by 4057
Abstract
Doxorubicin (DOX) is a widely used first-line antitumor agent; however, acquired drug resistance and side effects have become the main challenges to effective cancer therapy. Herein, DOX is loaded into iron-rich metal–organic framework/tannic acid (TA) nanocomplex to form a tumor-targeting and acid-activatable drug [...] Read more.
Doxorubicin (DOX) is a widely used first-line antitumor agent; however, acquired drug resistance and side effects have become the main challenges to effective cancer therapy. Herein, DOX is loaded into iron-rich metal–organic framework/tannic acid (TA) nanocomplex to form a tumor-targeting and acid-activatable drug delivery system (MOF/TA-DOX, MTD). Under the acidic tumor microenvironment, MTD simultaneously releases DOX and ferrous ion (Fe2+) accompanied by degradation. Apart from the chemotherapeutic effect, DOX elevates the intracellular H2O2 levels through cascade reactions, which will be beneficial to the Fenton reaction between the Fe2+ and H2O2, to persistently produce hydroxyl radicals (•OH). Thus, MTD efficiently mediates chemodynamic therapy (CDT) and remarkably enhances the sensitivity of chemotherapy. More encouragingly, the cancer cell killing efficiency of MTD is up to ~86% even at the ultralow equivalent concentration of DOX (2.26 μg/mL), while the viability of normal cells remained >88% at the same concentration of MTD. Taken together, MTD is expected to serve as drug-delivery nanoplatforms and •OH nanogenerators for improving chemo/chemodynamic synergistic therapy and reducing the toxic side effects. Full article
(This article belongs to the Special Issue Development and Applications of Nanomaterials for Novel Cancer Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop